Shots:
- The US FDA has approved ziresovir (AK0529) for a P-II trial in the severely ill RSV infected infant patients, including those in the pediatric intensive care unit (PICU)
- The trial will compare ziresovir with PBO to evaluate clinical efficacy, particularly oxygen-treatment duration & sustained recovery time, generating data to support future registrational trials
- In a Chinese study on pts aged 1–24 mos., ziresovir significantly reduced viral load, accelerated respiratory symptom resolution, & lowered the risk of recurrent wheezing and asthma over 24 mos. Findings were published in The NEJM & The Lancet Child & Adolescent Health
Ref: PRnewswire | Image: ArkBio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
